Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2025-02-04 00:00:00 ET · period of report 2025-01-31 · accession 0001415889-25-003065 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-04 | 2025-02-03 | TVTX | Dube Eric M | CEO, Dir | S - Sale | $20.21 | -50.7K | 430.5K | -11% | -$1.02M |
| D | 2025-02-04 | 2025-01-31 | TVTX | Dube Eric M | CEO, Dir | A - Grant | $0.00 | +130.0K | 481.2K | +37% | $0 |
| D | 2025-02-04 | 2025-01-31 | TVTX | Dube Eric M | CEO, Dir | A - Grant | $0.00 | +260.0K | 260.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-03 | S | D | 50,691 | $20.21 | 430,548 | D | — | — | (F3) The weighted average sale price for the transaction reported was $20.2076, and the range of prices were between $19.76 and $20.56. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 2 | Common | Common Stock | 2025-01-31 | A | A | 130,000 | $0.00 | 481,239 | D | — | — | |
| 3 | Derivative | Employee stock option (right to buy) | 2025-01-31 | A | A | 260,000 | $0.00 | 260,000 | D | $20.46 · — to 2035-01-31 | 260,000 Common Stock | (F4) One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. |